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The importance of PDHK (pyruvate dehydrogenase kinase) 2 and
4 in regulation of the PDH complex (pyruvate dehydrogenase
complex) was assessed in single- and double-knockout mice.
PDHK2 deficiency caused higher PDH complex activity and lower
blood glucose levels in the fed, but not the fasted, state. PDHK4
deficiency caused similar effects, but only after fasting. Double
deficiency intensified these effects in both the fed and fasted
states. PDHK2 deficiency had no effect on glucose tolerance,
PDHK4 deficiency produced only a modest effect, but double
deficiency caused a marked improvement and also induced lower
insulin levels and increased insulin sensitivity. In spite of these
beneficial effects, the double-knockout mice were more sensitive
than wild-type and single-knockout mice to long-term fasting,
succumbing to hypoglycaemia, ketoacidosis and hypothermia.
Stable isotope flux analysis indicated that hypoglycaemia was
due to a reduced rate of gluconeogenesis and that slightly more
glucose was converted into ketone bodies in the double-knockout
mice. The findings establish that PDHK2 is more important in
the fed state, PDHK4 is more important in the fasted state, and
survival during long-term fasting depends upon regulation of the
PDH complex by both PDHK2 and PDHK4.
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INTRODUCTION
The PDH complex (pyruvate dehydrogenase complex) plays a
pivotal role in controlling the concentrations of glucose in the fed
and fasted state [1]. In the well-fed state, the PDH complex is
highly active, promoting glucose oxidation by generating acetyl-
CoA, which can be oxidized by the citric acid cycle or used for
fatty acid and cholesterol synthesis. In the fasted state, the PDH
complex is inactivated by phosphorylation by PDHKs (pyruvate
dehydrogenase kinases) to conserve three carbon compounds for
the production of glucose [2].
The four PDHK isoenzymes responsible for phosphorylating
the PDH complex are expressed in a tissue-specific manner [3–
5]. Among the four, PDHK2 and PDHK4 are most abundantly
expressed in the heart [5–7], skeletal muscle [5,8–10] and liver
[5,11–14] of fasted mice. Of these two, PDHK2 is of interest
because of its greater sensitivity to activation by acetyl-CoA and
NADH and inhibition by pyruvate [15]. However, PDHK4 has
received greater attention because its expression is increased in
many tissues by fasting and diabetes [12] and transcription of its
gene is regulated by insulin, glucocorticoids, thyroid hormone
and fatty acids [16,17]. Inactivation of the PDH complex by
phosphorylation helps to maintain euglycaemia during fasting, but
contributes to hyperglycaemia in Type 2 diabetics. The increase
in PDHK activity in diabetes raises the question of whether the
PDHKs should be considered therapeutic targets for the treatment
of diabetes [18]. Support for this possibility has been provided by
the finding that mice lacking PDHK4 are euglycaemic in the fasted
state and are more glucose tolerant than wild-type mice fed on a
high-fat diet [19–21].
In the present study, PDHK2-KO (knockout) mice were
produced to determine the importance of this isoform in glucose
homoeostasis. In contrast with PDHK4-KO mice, blood glucose
levels were not lowered in the fasting state and glucose tolerance
was not improved in mice lacking PDHK2. This raised the
question of whether the presence of PDHK4 compensates for
the lack of PDHK2 and vice versa. To answer this question,
PDHK2/PDHK4-DKO (double-knockout) mice were produced
and characterized. In contrast with the relatively mild phenotypes
of the single-KO mice, the DKO mice are unable to tolerate
fasting for extended periods of time. The findings show that
survival during fasting depends upon inactivation of the PDH
complex by PDHK2 and/or PDHK4.
MATERIALS AND METHODS
Generation of the PDHK2/PDHK4-DKO mice
The procedures used to generate Pdk4− / − (homozygous PDHK4-
KO mice) C57BL/6J black mice [19] and Pdk2− / − (homozygous
PDHK2-KO mice) C57BL/6J black mice [22] have been
described previously. PDHK2-KO mice were crossed with
PDHK4-KO mice to produce PDHK2/PDHK4-DKO mice. Age-
matched wild-type mice were produced from the C57BL/6J black
mice (The Jackson Laboratory, Bar Harbor, ME, U.S.A.) that were
used to stabilize the genetic backgrounds of the PDHK2-KO and
PDHK4-KO mice.
Animal protocols
Mice were housed in an AALAC (American Association for
Laboratory Animal Care)-approved pathogen-free barrier facility
(12 h light/12 h dark cycles with temperature maintained at
23 +− 2 ◦C) and ad libitum fed on a standard rodent chow diet
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(Harlan; #7071). Studies were conducted with the approval of
the Institutional Animal Care and Use Committee of Indiana
University School of Medicine. Blood was collected from either
a tail vein or the submandibular vein for the determination
of metabolite levels. To determine PDH complex activity and
phosphorylation states, mice were anaesthetized by injecting
pentobarbital (60 mg/kg of body weight) intraperitoneally. Blood
was drawn from the inferior vena cava to measure metabolites.
Gastrocnemius muscle, liver, heart, kidney, testes and brain were
harvested as rapidly as possible followed by immediate freeze-
clamping with Wollenberger tongs at the temperature of liquid
nitrogen, powdered in liquid nitrogen and stored at − 85 ◦C
for analysis. Body temperature was determined with a rectal
temperature probe (MicroTherma 2T; Braintree Scientific).
Glucose-, insulin- and pyruvate-tolerance tests
Glucose-tolerance tests were performed after mice had been
fasted overnight (17:00 h–09:00 h). Glucose (2 g/kg of body
weight) was administered by intraperitoneal injection followed
by measurement of glucose in tail blood by a glucometer (Accu-
Check; Roche) at 0, 15, 30, 60 and 120 min after injection. Insulin-
tolerance tests were conducted after 6 h of fasting (08:00 h–
14:00 h). Insulin (0.5 unit/kg of body weight; Humulin R, Eli
Lilly) was administered by intraperitoneal injection. Tail blood
was taken for determination of glucose levels at 0, 15, 30, 60 and
120 min after injection. Mice were fasted overnight (17:00 h–
09:00 h) for the pyruvate-tolerance test. Pyruvate (1.5 g/kg of
body weight) was delivered by intraperitoneal injection followed
by collection of tail blood for measuring glucose at 0, 15, 30, 60
and 120 min. Blood was collected from the jugular vein 30 min
after pyruvate administration.
Measurement of metabolite concentrations in blood and liver
Serum was deproteinized with 7% perchloric acid followed
by neutralization with KOH and precipitation of KClO4.
Pyruvate [23], lactate [24], alanine [25], acetoacetate [26], β-
hydroxybutyrate [26], and branched-chain amino acids and α-keto
acids [27] were assayed by enzymatic methods. Triacylglycerols
were extracted with isopropyl alcohol and determined with an
L-type TG H assay kit (Wako Chemicals, Richmond, VA).
NEFAs (non-esterified fatty acids) were assayed by the NEFA
Half Micro Assay kit (Roche Diagnostics). Blood pH, pCO2 and
bicarbonate levels were measured with an I-STAT clinical analyser
with EC8 + cartridges (Heska Corporation). Liver glycogen was
measured by an enzymatic method [28].
Metabolic flux analysis in the fasting condition
Metabolic flux analysis was determined with stable-isotope-
labelled glucose as described previously [29,30]. Mice that had
been fasted for 3 h (16:00 h–19:00 h) were anaesthetized with
5% isoflurane and surgically implanted subcutaneously with
pre-activated mini-osmotic pumps (model 2001D; 8 μl/h; Alzet
Osmotic Pumps) containing 50 mg of [U-13C6]glucose (99.9%
enriched; Isotech) dissolved in 200 μl of water. Blood was collec-
ted from the mice between 10:00 h and 11:00 h the next morning.
Mass isotopomer analysis using GC–MS
Lactate and β-hydroxybutyrate were extracted from plasma
with ethyl acetate. The residue obtained by drying the
extract was treated with bis-trimethylsilyl trifluoroacetamide
and trimethylchlorosilane (99:1, v/v) (Sulpelco) before GC–MS
analysis as described by Des Rosiers et al. [31]. Analyses were
performed on a Hewlett Packard Mass Selective Detector (model
5973A) connected to a Hewlett Packard Gas Chromatograph
(model 5890) using chemical ionization with a ZB5 capillary
column (30 m length×250 μm internal diameter×0.25 μm film
thickness) (Phenomenex), with methane as carrier gas with a
flow rate of 1.0 ml/min, sample injector temperature 150 ◦C, and
oven temperature held at 70 ◦C for 5 min and programmed at
a ramp of 10 ◦C/min to 150 ◦C. The clusters around m/z 219
and m/z 233 were monitored for isotopomer calculation. For
glucose analysis, the aqueous phase was deproteinized, deionized,
dried and treated with hydroxylamine hydrochloride and acetic
anhydride to form aldonitrile penta-acetate derivatives for GC–
MS analysis as described by Szafranek et al. [32] with methane
as carrier gas with a flow rate of 1.0 ml/min, sample injector
temperature 250 ◦C, and oven temperature programmed from 210
to 250 ◦C at a ramp of 10 ◦C/min. The ion clusters around m/z 328
were monitored (m/z 327 to m/z 336).
Mass isotopomer distribution was determined from the mass
spectra as described previously [33,34]. The method corrects for
the contribution of derivatizing agent and natural 13C abundance to
mass isotopomer distribution of the compound of interest and also
for the presence of small amounts of m4 and m5 in the infused [U-
13C6]glucose. Data for the mass isotopomers in glucose, lactate,
or β-hydroxybutyrate are reported as molar fractions of m0,
m1, m2, etc. according to the number of labelled carbons in
the molecule [33,34]. The enrichment of a certain 13C-labelled
molecule is defined as its molar fraction mi, the fraction of
molecules with i being the number of 13C substitutions. The sum
of all isotopomers of the molecules, mi for i = 0 to n (n = 3,
4 or 6 for lactate, β-hydroxybutyrate and glucose respectively),
is equal to 1 or 100%. Substrate production or turnover rates
were determined using the principle of tracer dilution. At isotopic
steady state, the HGP (hepatic glucose production) rate was
determined from the equation [35] HGP (mg/min/kg) = (working
pump rate)/m6 − working pump rate, where m6 = final substrate
enrichment in glucose [29].
The PDH complex produces [1,2-13C2]acetyl-CoA (m2-
acetyl-CoA) from [U-13C6]glucose which can be incorporated
into β-hydroxybutyrate with the formation of [1,2-13C2]β-
hydroxybutyrate or [3,4-13C2]β-hydroxybutyrate, designated
hereafter as m2-β-hydroxybutyrate. The amount of the ketone
bodies in the blood produced from glucose was determined
from the equation: ketone bodies produced from glucose
(mmol/l) = [KB]×m2/(m6×2), where [KB] = sum of plasma
concentrations of β-hydroxybutyrate and acetoacetate in mmol/l,
m2 = 13C isotopomer enrichment in β-hydroxybutyrate, m6 = 13C
isotopomer enrichment in glucose. The factor 2 in the equation
corrects for the two acetyl-CoA units required to produce β-
hydroxybutyrate. The sum of β-hydroxybutyrate and acetoacetate
is used since both ketone bodies are assumed to be in equilibrium.
Measurement of enzyme activities
For the determination of PDH complex activity, tissues were
pulverized in liquid nitrogen and homogenized with a motor-
driven Teflon homogenizer in 5 vol. (w/v) of extraction
buffer containing 30 mM Hepes/KOH (pH 7.5), 3% (v/v)
Triton X-100, 2 mM EDTA, 2% (v/v) rat serum, 5 mM DTT
(dithiothreitol), 10 μM TPCK (tosylphenylalanylchloromethane),
10 μg/ml trypsin inhibitor, and 1 μM leupeptin. For the
determination of actual PDH complex activity, i.e. the activity
that exists in the intact tissue as a result of the phosphorylation
state, an aliquot of tissue extract (16 μl) was mixed with an equal
volume of resuspension buffer containing 30 mM Hepes/KOH
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(pH 7.5), 1% Triton X-100, 0.2 mM EDTA, 2% (v/v) bovine
serum, 1 μM leupeptin, 5 mM DTT, 20 mM dichloroacetate and
100 mM KF. For the determination of total PDH complex activity,
i.e. the activity of the complex after complete dephosphorylation,
an aliquot of tissue extract (25 μl) was mixed with an equal
volume of an activation buffer (resuspension buffer containing
40 mM MgCl2, 1.5 mM CaCl2 and 1 μg of recombinant pyruvate
dehydrogenase phosphatase 1 protein). Complete activation
of the PDH complex by dephosphorylation was achieved by
incubating this mixture at 30 ◦C for 20 min. Activity of the
PDH complex was measured spectrophotometically in a 96-
well plate reader (Spectra Max 190, Molecular Devices) with
a coupled assay based on the reaction catalysed by arylamine
acetyltransferase as described previously [36]. One unit of PDH
complex activity corresponds to the acetylation of 1 μmol of
p-(p-aminophenylazo)-benzenesulfonate per min at 30 ◦C.
PEPCK (phosphoenolpyruvate carboxykinase) activity was
measured as described by Rajas et al. [37]. Glucose-6-phosphatase
activity was measured as described by Foster et al. [38].
Western blot analysis
Tissue powders (50–80 mg) prepared in liquid nitrogen were
homogenized with 8–10× (v/w) RIPA extraction buffer [25 mM
Tris/HCl (pH 7.4), 150 mM NaCl, 0.1% SDS, 0.5% deoxycholic
acid and 1% (v/v) Nonidet P40] containing HaltTM protease
inhibitor (1×) and phosphatase protease inhibitor cocktails
(1×) (Thermo Scientific). Protein was determined with a Bio-
Rad Laboratories Protein Assay Kit using BSA as standard.
Protein (10–30 μg) was separated by SDS/PAGE (10% gels)
[39] and transferred on to nitrocellulose membranes (Bio-
Rad Laboratories) by the semi-dry electroblotting method [8]
and probed with antibodies against phospho-Ser293-PDHE1α
(pyruvate dehydrogenase E1α) (AP1062; EMD Chemicals),
PDHK2 (SC-100534, Santa Cruz Biotechnology) and PDHK4
[19], HSP60 (heat-shock protein 60) (622562; Transduction
Laboratories) and PDHK1 (KAP-PK112; Stressgen). Rabbit
PDHK3 antiserum was generated by AbFrontier against the C-
terminal 19 amino acids (RDASKYKAKQDKIKSNRTF) that are
unique to PDHK3. By Western blot analysis, the antiserum against
this peptide detected a protein with the expected molecular mass
of 45 kDa in tissue extracts of organs (brain, kidney and testes)
known to express PDHK3 [5]. That this protein corresponded
to PDHK3 was confirmed by its absence in tissue extracts of
brain, kidney, and testes harvested from PDHK3-KO mice (kindly
provided by Dr Kirill M. Popov, University of Alabama at
Birmingham, Birmingham, AL, U.S.A.). Images of the Western
blots were processed with a Gel DockTM XR+ Imaging System
(Bio-Rad Laboratories).
Statistical analysis
The statistical significance of differences between groups was
determined by Student’s t test or one-way ANOVA when
appropriate. Results are either means +− S.D. or means +− S.E.M.
for the indicated number of independent samples. P < 0.05 was
considered statistically significant.
RESULTS
Fed and fasting blood glucose levels in PDHK2-KO, PDHK4-KO and
PDHK2/PDHK4-DKO mice
PDHK2-KO mice were generated to assess the importance of
this kinase in glucose homoeostasis during feeding and fasting.
Table 1 Blood glucose levels in wild-type, PDHK2-KO, PDHK4-KO and
PDHK2/PDHK4-DKO mice in the fed and fasted states
Mice were fasted overnight (12 h). *P < 0.05, compared with wild-type mice in the same
nutritional state determined by Student’s t test. #P < 0.05, compared with PDHK4-KO mice
in the fasted state determined by Student’s t test. n = 4 mice per group, except for n = 7 for
wild-type.
Blood glucose (mg/dl)
Genotype Fed Fasted
Wild-type 174 +− 6 94 +− 7
PDHK2-KO 149 +− 3* 87 +− 7
PDHK4-KO 177 +− 11 75 +− 2*
PDHK2/PDHK4-DKO 154 +− 4* 61 +− 2*#
PDHK2-KO mice are viable and do not differ from wild-type
mice in growth and body composition when fed on a standard
rodent chow diet (results not shown). Interestingly, relative to
wild-type mice, blood glucose levels of PDHK2-KO mice were
reduced in the fed, but not the fasted, state (Table 1). In contrast,
as we have reported previously [19], PDHK4-KO mice have
lower blood glucose levels in the fasted, but not the fed, state
(Table 1). Therefore, not surprisingly, knocking out both PDHK2
and PDHK4 to produce DKO mice resulted in significantly lower
blood glucose levels in both the fed and the fasted state, with the
effect greater in the fasted than the fed state (Table 1). To evaluate
further the effect of PDHK deficiency on glucose homoeostasis,
glucose-tolerance studies were conducted. Previously, we found
that glucose tolerance was mildly, but significantly, enhanced in
PDHK4-KO mice compared with wild-type mice (area under
the curve reduced by 17%, n = 12 per group, P < 0.01) [19].
In contrast, no difference in glucose-tolerance was found in
direct comparison of PDHK2-KO mice with wild-type mice
(Figure 1A). In spite of these findings, the tolerance of DKO
mice to glucose was remarkably improved (area under the curve
of 13413 +− 1176 compared with 26592 +− 2749 mg/dl per min
for wild-type mice; means +− S.E.M., n = 4 per group, P < 0.05)(Figure 1B). Insulin levels measured in blood collected 30 min
after initiation of the glucose-tolerance test were also lower
in the DKO mice (1.0 +− 0.2 for DKO mice compared with
2.5 +− 0.9 ng/ml for wild-type mice, means +− S.E.M., n = 4 per
group, P < 0.05), consistent with greater insulin-sensitivity in the
DKO mice.
To determine the effect of prolonged fasting on blood glucose
levels, mice of the four genotypes were concurrently fasted for
24 h. Relative to wild-type mice, 24 h of fasting significantly
lowered blood glucose levels in the PDHK4-KO and DKO mice,
but not in the PDHK2-KO (Figure 1C).
Since glucose and insulin levels were lower in the DKO mice
during the glucose-tolerance test, an insulin-tolerance test was
conducted to assess insulin-sensitivity. Insulin had a greater effect
on blood glucose levels in the DKO mice (Figure 1D; area above
the curve of 4800 +− 294 compared with 3634 +− 304 mg/dl per min
for wild-type mice, means +− S.E.M., n = 6 per group, P < 0.05),
indicating greater insulin-sensitivity than in wild-type mice.
Effect of knocking out PDHK2 and PDHK4 on PDH complex activity
state in the fed and fasted state
Consistent with lower blood glucose levels in the fed state, the
actual activity and activity state of PDH complex were increased in
the liver and skeletal muscle of PDHK2-KO and PDHK2/PDHK4-
DKO mice (Table 2). Likewise, consistent with the lack of an
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Table 2 PDH complex activity in tissues of wild-type, PDHK2-KO, PDHK4-KO and PDHK2/PDHK4-DKO mice in the fed state
*P < 0.05 compared with wild-type mice determined by Student’s t test. n = 5 mice per group.
Tissue Genotype Actual activity (μmol/min per g of tissue wet weight) Total activity (μmol/min per g of tissue wet weight) Activity state (% active)
Liver Wild-type 0.7 +− 0.1 2.47 +− 0.08 30 +− 4
PDHK2-KO 1.3 +− 0.1* 2.54 +− 0.08 51 +− 4*
PDHK4-KO 0.8 +− 0.2 2.3 +− 0.1 32 +− 8
PDHK2/PDHK4-DKO 1.2 +− 0.1* 2.28 +− 0.06 56 +− 5*
Skeletal muscle Wild-type 0.4 +− 0.1 3.7 +− 0.2 9 +− 2
PDHK2-KO 1.98 +− 0.04* 3.4 +− 0.3 62 +− 4*
PDHK4-KO 2.0 +− 0.4* 4.2 +− 0.4 49 +− 10*
PDHK2/PDHK4-DKO 4.0 +− 0.5* 5.7 +− 0.5* 76 +− 5*
Figure 1 Improved glucose-tolerance and increased insulin-sensitivity in PDHK2/PDHK4-DKO mice, but not PDHK2-KO mice
(A) Glucose-tolerance tests were performed on wild-type (WT) and PDHK2-KO mice; n = 4 for both. (B) Glucose-tolerance tests were conducted with wild-type (WT) and PDHK2/PDHK4-DKO mice;
n = 4 for both. (C) Food was removed from mice of the indicated genotypes for 24 h. Blood glucose levels were determined 0, 12 or 24 h after removal of food; n = 6 for wild-type (WT), PDHK2-KO
and PDHK4-KO mice; n = 5 for DKO mice. (D) Insulin-tolerance tests were performed on wild-type (WT) and PDHK2/PDHK4-DKO mice; n = 6 for both. Results are means +− S.E.M. *P < 0.05
relative to wild-type mice determined by Student’s t test.
effect on blood glucose level in the fed state, the actual activity
and activity state of PDH complex were not increased in the liver
of PDHK4-KO mice (Table 2). However, the actual activity of
the complex was increased significantly in the skeletal muscle.
Likewise, consistent with no effect on blood glucose levels in
the fasted state, actual PDH complex activity in PDHK2-KO
mice did not differ from that of wild-type mice in the liver and
skeletal muscle (Table 3). In contrast, PDH complex actual activity
was modestly enhanced in the liver and markedly increased in
the skeletal muscle of fasted PDHK4-KO mice (Table 3). In
spite of the absence of any effect of knocking out PDHK2, the
combined deficiency of PDHK2 and PDHK4 provoked a 3- and
4-fold increase in PDH complex activity in the liver and skeletal
muscle respectively. These findings suggest that PDHK2 is more
important in the fed state, whereas PDHK4 is more important
in the fasted state. This agrees with the higher level of PDHK2
expression in the fed state and the much greater induction of
PDHK4 in the fasted state [12]. In this regard, it is noteworthy
that double deficiency of PDHK2 and PDHK4 induced synergistic
effects on PDH complex activity in both the liver and the
muscle in the fasted state, but not in the fed state (Tables 2
and 3).
To confirm that increases in PDH complex activity are due
to decreased phosphorylation of the E1α subunit of the PDH
complex, the relative amounts of phosphorylated protein for the
primary phosphorylation site (Ser293) of the E1α subunit of
the PDH complex were determined by Western blot analysis with
a site-specific phosphoprotein antibody [40]. Since the greatest
increase in PDH complex activity was found in skeletal muscle of
PDHK2/PDHK4-deficient mice, levels of phosphorylated E1α-
Ser293 were determined in the skeletal muscle of wild-type,
PDHK2-KO, PDHK4-KO and DKO mice in the fed and fasted
state (Figure 2). As anticipated, levels of the phosphorylated E1α
subunit of the PDH complex relative to wild-type mice were
significantly reduced in PDHK2-KO and PDHK4-KO mice, and
dramatically lowered in DKO mice, consistent with the actual
activities of the PDH complex measured in the fed and fasted
states.
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Table 3 PDH complex activity in tissues of wild-type, PDHK2-KO, PDHK4-KO and PDHK2/PDHK4-DKO mice in the fasted state
Mice were fasted for 24 h. *P < 0.05 compared with wild-type mice. #P < 0.05 compared with PDHK4-KO mice determined by Student’s t test. n = 4 mice per group.
Tissue Genotype Actual activity (μmol/min per g of tissue wet weight) Total activity (μmol/min per g of tissue wet weight) Activity state (% active)
Liver Wild-type 0.21 +− 0.01 2.31 +− 0.09 9.2 +− 0.8
PDHK2-KO 0.17 +− 0.02 2.15 +− 0.04 8.1 +− 0.8
PDHK4-KO 0.28 +− 0.01* 2.28 +− 0.09 12.2 +− 0.8*
PDHK2/PDHK4-DKO 0.60 +− 0.09* 2.24 +− 0.10 27 +− 4*#
Skeletal muscle Wild-type 0.36 +− 0.01 2.56 +− 0.03 14.0 +− 0.4
PDHK2-KO 0.34 +− 0.02 2.56 +− 0.02 14.3 +− 0.8
PDHK4-KO 1.0 +− 0.1* 2.69 +− 0.02 39 +− 4*
PDHK2/PDHK4-DKO 1.85 +− 0.03* 2.73 +− 0.02 67 +− 1*#
Figure 2 Decreased phosphorylation of the PDH complex E1α subunit in the skeletal muscle of PDHK-KO mice
(A) Representative immunoblots of the Ser293-phosphorylated form of the PDH complex E1α subunit of skeletal muscle from wild-type (WT), PDHK2-KO, PDHK4-KO and PDHK2/PDHK4-DKO
mice. Molecular masses are indicated in kDa (KD). (B) Histograms constructed from data obtained by Western blot analysis. Results are means +− S.D. with n = 3 mice per group. **P < 0.01;
***P < 0.001 relative to wild-type mice determined by one-way ANOVA.
Blood concentrations of gluconeogenic precursors and ketone
bodies are greatly altered in PDHK2/PDHK4-DKO mice
Knocking out the PDHKs enhances PDH complex activity
and thereby increases pyruvate oxidation, resulting in lower
levels of pyruvate, lactate and alanine, the principal three-
carbon substrates for gluconeogenesis [19,41]. As predicted,
serum levels of lactate, pyruvate and alanine were significantly
lowered in overnight-fasted DKO mice (Table 4). Since pyruvate
is reduced more than lactate, the lactate/pyruvate ratio was
greatly elevated in the DKO mice compared with wild-type
mice. Branched-chain amino acids levels were elevated, but
branched-chain α-keto acids were reduced, consistent with the
reduced availability of the pyruvate required to recycle glutamate
back to α-ketoglutarate for transamination of the branched-
chain amino acids [19]. In contrast with the gluconeogenic
precursors, β-hydroxybutyrate and acetoacetate were greatly
increased in DKO mice (Table 4), in spite of no difference in
serum levels of NEFAs and triacylglycerol. As a result of a greater
increase in acetoacetate than in β-hydroxybutyrate, and in striking
contrast with the more reduced state of the lactate/pyruvate ratio,
the hepatic β-hydroxybutyrate/acetoacetate ratio was decreased
(1.3 +− 0.2 in DKO mice compared with 1.68 +− 0.09 in wild-type
mice, n = 6 mice per group, P < 0.05), indicating a more oxidized
mitochondrial matrix space in the DKO mice.
Table 4 Blood metabolic parameters of wild-type and DKO mice
Metabolites are given in units of mmol/l, except for triacylglycerol which is given in mg/dl.
*P < 0.05 compared with DKO mice. n = 4 mice per group.
Measurement Wild-type DKO
Lactate 2.64 +− 0.14* 1.49 +− 0.01
Pyruvate 0.107 +− 0.013* 0.029 +− 0.004
Alanine 0.21 +− 0.02* 0.11 +− 0.01
β-Hydroxybutyrate 0.92 +− 0.13* 3.85 +− 0.61
Acetoacetate (AcAc) 0.17 +− 0.02* 1.68 +− 0.03
Branched-chain amino acids 0.36 +− 0.03 0.87 +− 0.03
Branched-chain α-keto acids 0.060 +− 0.007* 0.041 +− 0.003
Triacylglycerol 103 +− 15 117 +− 32
[Lactate]/[pyruvate] 25 +− 2* 54 +− 7
[β-Hydroxybutyrate]/[acetoacetate] 5.5 +− 0.6* 2.3 +− 0.4
Fed and fasting liver glycogen levels in PDHK2-KO, PDHK4-KO and
PDK2/PDK4-DKO mice
In the fed state, liver glycogen levels of the DKO mice, but not the
single-KO mice, were significantly lower (17%) than that of
the wild-type mice (Figure 3A). After fasting for 24 h, liver
glycogen remained higher in the wild-type mice than in the
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Figure 3 Glycogen levels are reduced, pyruvate clearance is increased and the rate of glucose production is reduced in PDHK2/PDHK4-DKO mice
Liver glycogen levels in wild-type (WT), PDHK2-KO, PDHK4-KO and DKO mice in the fed state (A) and 24 h fasted state (B); n = 5 mice per group. (C) Blood glucose levels during pyruvate-tolerance
test with wild-type (WT) and PDHK2/PDHK4-DKO mice; n = 4 mice for both. (D) Glucose production rate in wild-type (WT) and DKO after 18 h of fasting was determined using constant infusion of
[U-13C6]glucose; n = 5 for wild-type; n = 6 for DKO. Results are means +− S.E.M. *P < 0.05; **P < 0.01 relative to wild-type mice determined by Student’s t test.
KO mice, higher in the PDHK2-KO mice than in the other KO
mice, and virtually depleted in the PDHK4-KO and DKO mice
(Figure 3B). When considered in combination with the effect
of fasting on blood glucose levels (Figure 1C), these findings
suggest that liver glycogen was used more rapidly to maintain
blood glucose levels in PDHK-deficient mice. Retention of larger
amounts of liver glycogen in the PDHK2-KO mice than in the
PDHK4 and DKO mice is consistent with less effect of fasting on
blood glucose levels.
Pyruvate tolerance and clearance is enhanced in DKO mice
To determine whether exogenous pyruvate would eliminate the
difference in fasting blood glucose levels between the wild-
type and DKO mice, pyruvate was administered according to
the standard pyruvate-tolerance test. The DKO mice showed a
greater tolerance to exogenous pyruvate than wild-type mice (area
under the curves of 5725 +− 30 and 8460 +− 735 arbitrary units
respectively, n = 4 mice/group, P < 0.02) (Figure 3C). Although
blood glucose levels of the DKO mice were not restored to those of
the wild-type, this can be explained by rapid clearance of pyruvate
from the blood of DKO mice.
Whereas serum pyruvate concentrations measured 15 min after
initiation of the test were high enough to maintain maximum
rates of gluconeogenesis in both the wild-type (1.8 +− 0.3 mM)
and DKO mice (0.7 +− 0.1 mM, means +− S.E.M., n = 5 mice per
group, P < 0.05), the levels measured after 30 min were too
low (0.039 +− 0.002 in DKO mice compared with 0.53 +− 0.04 mM
for wild-type mice, means +− S.E.M., n = 5 mice per group,
P < 0.001) and the lactate/pyruvate ratio was too high [42] in
the DKO mice (106 +− 18 compared with 18 +− 4 for wild-type
mice, means +− S.E.M., n = 5 mice per group, P < 0.01).
The alanine concentration measured at 30 min in the DKO mice
(0.041 +− 0.009 compared with 0.32 +− 0.04 mM for wild-type
mice, means +− S.E.M., n = 5 mice per group, P < 0.01) was also
too low for maximum rates of glucose synthesis. During the first
15 min of the test, glucose levels increased at comparable rates
in wild-type and DKO mice (3.7 +− 0.3 and 3.4 +− 0.3 mg/dl per
min respectively, n = 4 mice/group, not significantly different).
As expected from the concentrations of pyruvate and alanine
measured, the rate of increase in glucose during the second
15 min of the test remained the same in the wild-type mice,
but fell off dramatically in the DKO mice (2.3 +− 0.5 compared
with 3.9 +− 0.3 mg/dl per min for wild-type mice). Therefore,
under conditions of saturating concentrations of gluconeogenic
substrates, i.e. the first 15 min of the test, no difference in rates of
increase in glucose concentration were found between wild-type
and DKO mice, suggesting comparable enzymatic capacity for
gluconeogenesis in DKO and wild-type mice.
Activities of key gluconeogenic enzymes are not reduced in the
liver of DKO mice
Consistent with the results of the pyruvate-tolerance test, the
activity of hepatic PEPCK was not different between the wild-type
and DKO mice (1.50 +− 0.2 compared with 1.25 +− 0.15 μmol/min
per g of wet weight for wild-type, mean +− S.E.M., n = 5 mice per
group, P = 0.30) and the activity of glucose-6-phosphatase was
greater rather than reduced in the DKO mice (1.54 +− 0.13
compared with 1.01 +− 0.18 μmol/min per g of wet weight for
wild-type mice, n = 5 per group, P < 0.05), suggesting that
reduced enzymatic capacity for hepatic gluconeogenesis is not
responsible for lower blood glucose levels in the DKO mice.
Rate of glucose production is decreased in DKO mice
Stable-isotope-based metabolic flux measurements with [U-
13C6]glucose revealed a 52% lower rate of glucose production
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Figure 4 Conversion of glucose into ketone bodies and blood ketone bodies is increased in PDHK2/PDHK4-DKO mice
(A) Plasma ketone bodies (KB) (β-hydroxybutyrate + acetoacetate) produced from glucose in wild-type (WT) and DKO mice after 18 h of fasting was determined using constant infusion of
[U-13C6]glucose; n = 5 for wild-type; n = 6 for DKO. (B) Plasma NEFA levels were determined in male wild-type (WT) and PDHK2/PDHK4-DKO mice after overnight fasting; n = 4 for both. (C and
D) Plasma acetoacetate (C) and β-hydroxybutyrate (D) levels were determined in male wild-type (WT), PDHK2-KO, PDHK4-KO and PDHK2/PDHK4-DKO mice 0, 12, 24 or 36 h after removal of
food. Results are means +− S.E.M. with n = 5 in each group for each time point. *P < 0.05; **P < 0.01; ***P < 0.001 relative to wild-type mice determined by Student’s t test.
in DKO mice relative to wild-type mice (Figure 3D). Therefore
the lower blood glucose levels seen in the DKO mice can be
explained at least in part by a lower rate of glucose production,
which is consistent with the hypothesis that substrate supply limits
the rate of gluconeogenesis in PDHK-deficient mice.
Contribution of acetyl-CoA produced by the PDH complex to ketone
body production in DKO mice
In the fasted state, ketone bodies are primarily derived from acetyl-
CoA produced by the oxidation of fatty acids in the liver. Synthesis
of ketone bodies from glucose and the three-carbon compounds
derived from glucose is largely prevented by inactivation of the
PDH complex by phosphorylation. Because the PDH complex
remains partially active in the fasted state in DKO mice, glucose
should contribute more carbon to the synthesis of ketone bodies
in these mice. This was examined by measuring the incorporation
of carbon from [U-13C6]glucose into ketone bodies in wild-
type and DKO mice. As anticipated, greater β-hydroxybutyrate
enrichment with two [13C]carbons (m2-β-hydroxybutyrate) was
found in the plasma of the DKO mice, which, combined with
the greater concentration of ketone bodies in the DKO mice,
established that more ketone bodies were produced from glucose
in the DKO mice than in the wild-type mice (Figure 4A).
This finding is consistent with greater flux through the PDH
complex with subsequent conversion of acetyl-CoA into ketone
bodies. However, the relative contribution of glucose carbon
to the formation of ketone bodies was minuscule (<1% in both
the wild-type and DKO mice) relative to other carbon sources,
which presumably were almost entirely fatty acids. Since serum
levels of NEFAs were similar between DKO and wild-type mice
(Figure 4B), greater availability of fatty acids for oxidation does
not explain the increase in ketone bodies.
Fasting induces ketoacidosis and hypothermia in the DKO mice
PDHK4-KO mice tolerate fasting without evidence of metabolic
decompensation [19–21]. Since preliminary studies suggested
that DKO mice are more sensitive to fasting, the metabolic
effects of fasting for various periods of time were determined
with wild-type, single-KO and DKO mice (Figures 4C and 4D).
Relative to wild-type mice, a modest, but significant, increase
in β-hydroxybutyrate occurred after 12 h, but not after 24 and
36 h, of fasting in PDHK2-KO mice (Figure 4D). In PDHK4-
KO mice, acetoacetate was significantly increased after 24 and
36 h of fasting and β-hydroxybutyrate after 36 h of fasting. In
the DKO mice, fasting induced much higher levels of both
ketone bodies throughout the study than observed in the other
genotypes. Fasting for 36 h induced nearly a 5-fold increase in
acetoacetate in DKO mice compared with wild-type mice and
a 2.5-fold increase compared with PDHK4 KO (Figure 4C). In
addition, the concentration of β-hydroxybutyrate was elevated
approximately 4-fold in the DKO mice compared with wild-type
mice and 2-fold compared with PDHK4-KO mice (Figure 4D).
Because ketosis can induce metabolic acidosis, the blood pH
of the DKO mice was determined. Fasting for 4 h significantly
lowered blood pH in the DKO mice compared with wild-type
mice (7.08 +− 0.03 and 7.20 +− 0.06 respectively; Figure 5A). After
24 h of fasting, blood pH of the DKO mice reached dangerously
low levels (6.87 +− 0.07 and 7.22 +− 0.03 respectively) owing to
severe ketoacidosis. Unlike the response of the DKO mice,
36 h of fasting did not lower blood pH of PDHK2-KO and
PDHK4-KO mice (Figure 5B). As expected, with the presence
of acidosis, the concentration of bicarbonate was dramatically
reduced in the DKO mice (9 +− 2 mmol/l) compared with wild-
type mice (20.7 +− 0.7 mmol/l) (Figure 5C). Furthermore, pCO2
was significantly reduced in DKO mice (25 +− 4 compared with
40 +− 6 mmHg for wild-type mice, means +− S.E.M., n = 4 per
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Figure 5 Fasting induces acidosis in PDHK2/PDHK4-DKO mice
(A) Blood pH was determined in wild-type (WT) and PDHK2/PDHK4-DKO mice during fasting; n = 5 for both. (B and C) Blood pH (B) and bicarbonate (C) were determined in wild-type (WT),
PDHK2-KO, PDHK4-KO and PDHK2/PDHK4-DKO mice during fasting. Results are means +− S.E.M. with n = 4 per group. *P < 0.05; **P < 0.01; ***P < 0.001 relative to wild-type mice determined
by Student’s t test.
Figure 6 Deficiency of PDHK2, PDHK4, and both PDHK2 and PDHK4 does not increase expression of other PDHK isoforms in the heart, liver and skeletal
muscle
Protein levels of PDHK2, PDHK4 and PDHK1 were determined by Western blot analysis in the heart (A), liver (B) and skeletal muscle (C) of wild-type (WT), PDHK4-KO mice, PDHK2-KO mice and
PDHK2/PDHK4-DKO mice.
group, P < 0.05). In addition to suffering from ketoacidosis,
the DKO mice experienced hypothermia (27 +− 2 compared with
34.5 +− 0.7 ◦C in wild-type mice, n = 5 mice per group, P < 0.05)
after 36 h of fasting, leading ultimately to their death.
Expression of PDHK4 does not compensate for a lack of PDHK2 in
PDHK2-KO mice and vice versa
PDHK2 and PDHK4 were measured by Western blot analysis to
assess whether altered expression of these proteins compensates
for the lack of PDHK2 and PDHK4 in the corresponding KO mice
(Figure 6). Protein levels of PDHK2 were not changed in the
tissues of the PDHK4-KO mice compared with wild-type mice.
Protein levels of PDHK4 were likewise similar in heart, liver and
skeletal muscle of PDHK2-KO mice and wild-type mice. These
findings suggest that, in the fasted state, expression of PDHK2
does not compensate for the lack of PDHK4 and expression of
PDHK4 does not compensate for the lack of PDHK2.
Expression of PDHK1 and PDHK3 does not compensate for the lack
of PDHK2 and PDHK4 in the DKO mice
Protein levels of PDHK1 were similar in the liver and skeletal
muscle of wild-type, PDHK2-KO and PDHK4-KO mice (results
not shown), suggesting that PDHK1 does not compensate for the
loss of PDHK2 or PDHK4. Furthermore, the amounts of PDHK1
expressed in the liver and skeletal muscle were similar for wild-
type and DKO mice, but slightly reduced in the heart of DKO
mice (Figure 6). Therefore the expression of PDHK1 does not
compensate for the lack of PDHK2 and PDHK4 in the DKO
mice. PDHK3 protein could not be detected in the liver, skeletal
muscle and heart of wild-type and DKO mice with an antibody
that readily detects this protein in brain, testes and kidney (results
not shown).
DISCUSSION
The present study shows that PDHK2 deficiency lowers blood
glucose in the fed state without a large increase in ketone bodies,
PDHK4 deficiency lowers blood glucose in the fasted state with
a significant increase in ketone bodies, and a combined PDHK2
and PDHK4 deficiency lowers blood glucose in both the fed and
fasted states with an increase in ketone bodies that culminates in
metabolic acidosis and decompensation.
The finding that PDHK2 was effective in the fed state but not the
fasted state was unexpected, but can be rationalized on the basis
of the expression pattern and regulatory properties of PDHK2
relative to the other PDHKs. PDHK2 is constitutively expressed
in tissues in the fed and fasted state [12,43], its activity is more
sensitive than the other PDHKs to modulation by pyruvate, NADH
and acetyl-CoA [15,44], and its expression level is only modestly
increased by fasting in the liver and kidney of rats [8] and by
diabetes in Otsuka Long–Evans Tokushima Fatty rats [43], and
in Type 2 diabetes in humans [45]. Because these observations
seemed to suggest an important role for PDHK2 in the regulation
of glucose metabolism during fasting and in diabetes, we were
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surprised to find that blood glucose is maintained at normal fasting
levels in PDHK2-KO mice. Consistent with this observation,
knocking out PDHK2 had no effect upon the phosphorylation
and activity state of the PDH complex in the fasted state in either
the liver or the skeletal muscle. Because PDHK2 deficiency does
not alter PDH complex activity, the rate of pyruvate oxidation
is not increased and therefore the supply of three-carbon
compounds for hepatic and renal glucose production is not
affected in these mice. Since gluconeogenesis was not limited
by substrate supply, glucose levels were not affected.
In wild-type mice, the PDH complex is normally less
phosphorylated and more active in the fed state than in the
fasted state. Nevertheless, a large portion of the complex
remains phosphorylated and catalytically inactive in the fed state.
Therefore a considerable reserve of PDH complex activity exists
in the fed state that can be called into play by dephosphorylation
when needed. The present study suggests that PDHK2 plays an
important role in phosphorylating and therefore maintaining this
reserve of PDH complex activity in the fed state. Rendering mice
deficient in PDHK2 reduces this reserve, resulting in greater PDH
complex activity and therefore a greater rate of glucose disposal
and lower glucose levels in the fed state. Because gluconeogenesis
is inhibited in the fed state, lower blood glucose levels are not
the result of a reduced rate of glucose production, but, rather,
increased glucose disposal.
PDHK4 has received most of the attention in studies on
physiological regulation of the PDH complex because its
expression is more sensitive to the metabolic stress of fasting and
diabetes [8]. The expression of PDHK4 is remarkably sensitive
to stimulation by glucocorticoids and PPAR (peroxisome-
proliferator-activated receptor) α and δ ligands and to inhibition
by insulin [16,46,47], consistent with an important role for
PDHK4 in setting the phosphorylation and activity state of PDH
complex in fasting and diabetes. In addition, fasting blood glucose
levels are significantly reduced in PDHK4-KO mice relative to
that of corresponding control mice [19,20]. In the present study,
the phosphorylation state of the PDH complex was found to be
reduced in PDHK4-KO mice, consistent with the increase in the
PDH complex activity state reported previously [17]. Lactate,
pyruvate and alanine levels are therefore reduced in PDHK4-KO
mice, resulting in lower blood glucose levels for want of three-
carbon compounds for gluconeogenesis. In the fed state, PDHK4
deficiency has no effect on blood glucose because PDHK4 is not
expressed at high enough levels to affect the activity state of PDH
complex. PDHK4 is effective in the fasted state because of the
higher level of its expression and therefore its greater importance
in regulation of PDH complex.
Double deficiency of PDHK2 and PDHK4 greatly increased
PDH complex activity and reduced blood glucose levels in both
the fed and the fasted state. Whereas a greater rate of glucose
oxidation can explain the reduced level of blood glucose in the
fed state, the reduced concentrations of pyruvate, alanine and
lactate suggest that a decreased supply of substrates needed for
gluconeogenesis is the mechanism by which double deficiency of
PDHK2 and PDHK4 reduces blood glucose levels in the fasted
state. Consistent with this hypothesis, metabolic flux analysis with
[U-13C6]glucose indicated that DKO mice synthesized glucose at
a lower rate than did wild-type mice. Furthermore, no difference
in PEPCK activity, which limits the rate of gluconeogenesis under
some conditions, was found between DKO and wild-type mice.
Furthermore, glucose-6-phosphatase was slightly elevated rather
than reduced in DKO mice. These findings suggest that altered
enzymatic capacity for gluconeogenesis is not responsible for
lower blood glucose levels in DKO mice. It is therefore more
likely that reduced substrate supply for gluconeogenesis limits the
rate of hepatic/renal glucose production in the DKO mice. These
data support findings with the PDHK inhibitor dichloroacetate
[41,48,49], which lowers blood glucose levels by reducing the rate
of gluconeogenesis by decreasing the blood levels of pyruvate,
lactate and alanine [41].
Even though PDHK deficiency results in lower blood glucose
levels [19] and may therefore serve as a therapeutic target for
Type 2 diabetes [18], lack of control of PDH complex activity
by PDHK2 and PDHK4 greatly increases blood ketone body
levels. Overnight fasting of DKO mice caused a 4-fold increase
in β-hydroxybutyrate and a 10-fold increase in acetoacetate.
Ketone bodies were not significantly affected in PDHK2-KO
mice compared with wild-type mice, and, although elevated in
the PDHK4-KO mice, ketone body levels in these mice remained
much lower than in the DKO mice. Furthermore, acidosis was
induced by the ketosis in DKO mice, resulting in fatally low
blood pH after 24 h of food deprivation. Although PDHK4-KO
mice have elevated ketone bodies, these animals maintain blood
pH levels in the normal range. Therefore PDHK2 and PDHK4
are essential for preventing ketoacidosis during fasting. At least
in part, this is because inhibition of the PDH complex by PDHK2
and PDHK4 prevents competition between pyruvate and ketone
body oxidation in peripheral tissues [19]. Studies with the PDHK
inhibitor dichloroacetate showed that increased glucose oxidation
inhibits ketone body oxidation [41]. In addition, inhibition of
the PDH complex by PDHK2 and PDHK4 limits the conversion
of the carbon of glucose and gluconeogenic precursors into
ketone bodies. Normally, the PDH complex is inactive in the
fasted state and acetyl-CoA, which is derived primarily from fatty
acid oxidation, produces ketone bodies. The greater enrichment
of ketone bodies with m2 β-hydroxybutyrate originating from
[U-13C6]glucose shows that knocking out PDHK2 and PDHK4
increases PDH complex activity, resulting in production of acetyl-
CoA from pyruvate that can be used to synthesize ketone bodies,
although in insignificant amounts relative to the ketone bodies
formed from fatty acids.
In contrast with the single-KO mice, PDH complex activity
is greatly increased in the liver and skeletal muscle of the
PDHK2/PDHK4-DKO mice, resulting in mice that cannot
survive an extended period of fasting because of hypoglycaemia,
ketoacidosis and hypothermia. Since PDHK2-KO and PDHK4-
KO mice have mild phenotypes compared with the DKO mice,
we predicted that compensation by increased expression of the
other PDHKs might protect single-KO mice from deleterious
effects experienced by the DKO mice. However, the expression
of PDHK2 does not compensate for the lack of PDHK4 and
the expression of PDHK4 does not compensate for the lack
of PDHK2. Therefore the modest phenotype of the PDHK2-
KO and PDHK4-KO mice relative to the DKO mice is not
due to up-regulation of the expression of PDHK2 or PDHK4.
Instead, the intrinsic activity of PDHK4 and its sensitivity to
stimulation by acetyl-CoA and NADH [15] may be sufficient
to cover for the absence of PDHK2. Likewise, PDHK2 may be
able to cover partially, but less effectively, for the absence of
PDHK4 in PDHK4-KO mice. The phenotype of the DKO mice
is much more severe because these compensatory effects are not
possible, and also because PDHK1 and PDHK3 are unable to
cover for the absence of PDHK2 and PDHK4.
The present study documents a precaution relative to the
potential use of PDHK inhibitors for the treatment of diabetes.
Double deficiency of PDHK2 and PDHK4 renders mice sensitive
to hypoglycaemia, ketoacidosis and hypothermia during fasting.
Previous studies have shown that knocking out PDHK4 inhibits
fatty acid oxidation in isolated diaphragms, suggesting that PDHK
deficiency impairs peripheral fatty acid oxidation, resulting in
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hypothermia in DKO mice [19]. From these findings, it is clear
that compounds that totally inhibit PDHK2 and PDHK4 would
have deleterious effects. Finally, it is noted that children with
idiopathic ketoacidotic hypoglycaemia suffer fasting-induced
hypoglycaemia and ketoacidaemia as a result of reduced levels
of the gluconeogenic precursors [50]. Since similar effects are
observed in PDHK2/PDHK4-DKO mice, PDHK deficiency is a
potential cause and these mice might serve as an animal model
for this disorder.
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